SavedAdd your journal

Journals / Türk Biyokimya Dergisi / 2021 / Cilt: 46 - Sayı: 5

The confounding effect of interleukin-6 on apoptosis of MCF-7 cells through down- regulation of MMP-2/-9 mRNA expression

nterlökin-6’nın MMP-2/-9 mRNA Ekspresyonunun Downregülasyonu Yoluyla MCF-7 Hücrelerinin Apoptozisi Üzerindeki Etkisi

Filiz Bakar-Ateş
Aybüke Çelik
Pages
549–555
Publication Date
2022-11-06
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

IL-6 treatment has also increased the early apoptotic cell population % in MCF-7 cells significantly (p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objectives: Breast cancer is the second cause of death among women worldwide.
📊
Key Findings & Data:Several stu- dies have indicated the pleiotrophic effect of Interleukin-6 (IL-6) via targeting the membrane-bound or soluble receptors.
💡
Conclusion & Impact:IL-6 treatment has also increased the early apoptotic cell population % in MCF-7 cells significantly (p
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objectives: Breast cancer is the second cause of death among women worldwide. In the last decades, the immunotherapy-based approaches have a growing importance in the treatment of breast cancer. Several stu- dies have indicated the pleiotrophic effect of Interleukin-6 (IL-6) via targeting the membrane-bound or soluble receptors. Materials and methods: Different concentrations of IL-6 were incubated for 24, 48, and 72 h in the breast carcinoma cell line (MCF-7). Cell proliferation, apoptotic cell popula- tion, gene expression by RT-PCR were measured, and the effect of IL-6 treatment on cell morphology was observed. Results: In the present study, IL-6 treatment of MCF-7 cells inhibited cell proliferation in a dose and time dependent manner. The IL-6 treatment was found most effective on 24 h. The viable cell amount was decreased to 70.07 ± 4.85% at 100 nM treatment with a significant alteration on cell morphology, simultaneously in the 24 h of treatment. IL-6 treatment has also increased the early apoptotic cell population % in MCF-7 cells significantly (p

Özet

Amaç: Meme kanseri, dünya çapında kadınlar arasında ikinci ölüm nedenidir. Son yıllarda, meme kanserinin tedavisinde immünoterapi temelli yaklaşımların önemi giderek artmaktadır. Çeşitli çalışmalar, interlökin-6’nın (IL-6), membrana bağlı veya çözünebilir reseptörleri hedef alarak pleiotropik etki gösterdiğini belirtmiştir. Gereç ve Yöntem: Farklı konsantrasyonlarda IL-6 (10, 25, 50, ve 100 nM) meme kanseri hücre hattında (MCF-7) 24, 48 ve 72 saat inkübe edilmiştir. İnkübasyondan sonra hücre proliferasyonu, apoptotik hücre popülasyonu, RT-PCR ile gen ekspresyonu ölçülmüş ve IL-6 tedavisinin hücre mor- folojisine etkisi gözlemlenmiştir. Sonuç: Mevcut çalışmada, MCF-7 hücrelerinde IL-6 teda- visi, hücre proliferasyonunu doza ve zamana bağımlı bir şekilde inhibe etmiştir. 24 saat inkübasyon sonrasında 100 nM IL-6 tedavisi ile canlı hücre miktarı %70.07 ± 4.85’e kadar azalmış, aynı zamanda hücre morfolojisinde anlamlı şekilde değişiklik gözlenmiştir. IL-6 tedavisi ayrıca MCF-7 hücrelerinde erken apoptotik hücre popülasyonu yüzde- sini önemli ölçüde artırmıştır (p

🔖

Cite This Article

Bakar-Ateş, F., Çelik, A. (2022). The confounding effect of interleukin-6 on apoptosis of MCF-7 cells through down- regulation of MMP-2/-9 mRNA expression. Türk Biyokimya Dergisi, Cilt: 46 - Sayı: 5, 549–555. https://ajindex.com/articles/620705

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (17)

  1. Waldmann TA. Immunotherapy: past, present and future. Nat Med 2003;9:269–77
  2. Khalil DN, Smith EL, Brentjens RJ, Wolchok JD. The future of cancer treatment: immunomodulation, CARs and combination immunotherapy. Nat Rev Clin Oncol 2016;13:394
  3. Chen DS, Mellman I. Oncology meets immunology: the cancer- immunity cycle. Immunity 2013;39:1–10
  4. Garcia-Aranda M, Redondo M. Immunotherapy: a challenge of breast cancer treatment. Cancers 2019;11. https://doi.org/10. 3390/cancers11121822
  5. Farkona S, Diamandis EP, Blasutig IM. Cancer immunotherapy: the beginning of the end of cancer? BMC Med 2016;14:73
  6. Rosenberg SA, Restifo NP. Adoptive cell transfer as personalized immunotherapy for human cancer. Science 2015;348:62–8
  7. Fesnak AD, June CH, Levine BL. Engineered T cells: the promise and challenges of cancer immunotherapy. Nat Rev Canc 2016;16: 566–81
  8. Zou W, Wolchok JD, Chen L. PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: mechanisms, response biomarkers, and combinations. Sci Transl Med 2016;8:328rv4
  9. Sharma P, Allison JP. The future of immune checkpoint therapy. Science 2015;348:56–61
  10. Rosenberg SA, Yang JC, Sherry RM, Kammula US, Hughes MS, Phan GQ, et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Canc Res 2011;17:4550–7
  11. Beatty GL, Gladney WL. Immune escape mechanisms as a guide for cancer immunotherapy. Clin Canc Res 2015;21:687–92
  12. Ohno Y, Toyoshima Y, Yurino H, Monma N, Xiang H, Sumida K, et al. Lack of interleukin-6 in the tumor microenvironment augments type-1 immunity and increases the efficacy of cancer immunotherapy. Canc Sci 2017;108:1959–66
  13. Masjedi A, Hashemi V, Hojjat-Farsangi M, Ghalamfarsa G, Azizi G, Yousefi M, et al. The significant role of interleukin-6 and its signaling pathway in the immunopathogenesis and treatment of breast cancer. Biomed Pharmacother 2018;108:1415–24
  14. Chan LC, Li CW, Xia W, Hsu JM, Lee HH, Cha JH, et al. IL-6/JAK1 pathway drives PD-L1 Y112 phosphorylation to promote cancer immune evasion. J Clin Invest 2019;129:3324–38
  15. Chen Q, Xu B, Lan L, Yang D, Yang M, Jiang J, et al. High mRNA expression level of IL-6R was associated with better prognosis for patients with ovarian cancer: a pooled meta-analysis. Sci Rep 2017;7:8769
  16. Girard JP, Moussion C, Forster R. HEVs, lymphatics and homeostatic immune cell trafficking in lymph nodes. Nat Rev Immunol 2012;12:762–73
  17. Kim SY, Kang JW,